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as a monotherapy. Remarkable activity has been observed in 
patients with BRCA1/2 mutations using Olaparib (AZD2281), 
an orally bioavailable PARP inhibitor, recently approved for 
refractory ovarian cancer with BRCA1/2 mutations. Toxicity 
with monotherapy has been remarkably low. Is the BRCA 
mutation story the only predictor of PARP inhibition (I) 
sensitivity? Perhaps other homologous and non-homologous 
repair defects may also contribute to PARP(I) sensitivity. 
Fanconi anemia phenotypes may also relate to sensitivity as 
well as pathways related to the SMAD family. We assessed 
the safety, toxicity and early response when combining 
escalating doses of Olaparib with fixed dose cetuximab and 
RT in heavy smoker HNSCC patients. We chose this group of 
patients due to their high local-regional failure rates and 
hypothesized amplified rates of HR defects that would lend 
itself to Olaparib sensitivity. We used a TITE-CRM model with 
a starting Olaparib dose of 50 mg po BID. The TITE-CRM 
algorithm uses both the length of observation and whether or 
not a DLT has occurred in each previous patient enrolled on 
the trial to estimate the probability of a DLT for each dose 
level, thereby optimizing subsequent dose assignment. We 
enrolled 13 patients to date. Among these patients, with a 
median follow-up of ~14 months, two failed distantly and one 
failed locally. Patients who experienced local/regional 
failures continued to smoke during treatment. Toxicity was 
primarily related to grade 3 dermatitis and acneiform rash. 
Skin toxicities resolved in all patients after treatment 
concluded; long-term follow up has revealed development of 
grade 2 fibrosis in the neck areas where dermatitis was most 
severe in four patients. The optimal timing of PARP inhibitors 
and radiation remains unknown and with dose enhancement 
factors seen pre-clinically, might it be possible to investigate 
radiation de-intensification or perhaps consider novel 
combinations with checkpoint inhibitors. This discussion will 
include a review of some of the pertinent pre-clinical studies 
with radiation, a review of toxicities and cautions as it 
relates to combinations with radiation and what are the 
possibilities for future approaches with DNA repair in locally 
advanced disease. 
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The α-β ratio for prostate cancer (PCa) is postulated to be 
low; < 3 Gy, i.e. even lower than for late normal tissue 
reactions. Hence hypofractionated radiotherapy (RT) is 
hypothesized to be advantageous for treatment of localized 
PCa. Literature data indicating that this is the case for a 
moderately hypofractionated regimen was first reported from 
Italy by Arcangeli. This study was however quite small. At 
ECC 2015 Dearnaley presented the results from the UK three-
armed CHHiP-trial comprising 3,200 patients. This three-
armed trial showed non-inferiority between the 74 Gy 
conventional arm (37 fr; 2 Gy/fr) and the 60 Gy moderately 
hypofractionated arms (20 fr; 3 Gy/fr) while the 
experimental arm given 57 Gy arm (19 fr; 3Gy/fr.) had lower 
efficacy. Patients had predominately intermediate risk 
tumours and most patients received 6 month of neoadjuvant 
and concomitant castration treatment. Previously published 
toxicity data from the trial showed similar results for the 
trial arms. Results from other moderately hypofractionated 
schedules have also been reported recently. RTOG 0415 with 
only low-risk patients, showed that 70 Gy in 28 fr over 5.6 
weeks is non-inferior to 73.8 Gy in 41 fr over 8.2 weeks for 
low risk PCa patients. The Dutch randomised phase III HYPRO 
trial with 804 evaluable patients with intermediate/high-risk 
PCa, comparing moderately hypofractionated RT (19 fr; 3.4 
Gy/fr.) with conventional RT (39 fr; 2 Gy/fr), showed non-
inferiority with comparable toxicity.  
Some prospective results of Sterotactic Body RadioTherapy 
(SBRT) with 5 fractions and 7-8 Gy/fr suggest equal clinical 
outcome compared to conventional RT and with acceptable 
toxicity. The Scandinavian multicentre phase III trial “HYPO-
RT-PC” was recently closed, with 1200 patients recruited 
during 2005-2015. All patients had intermediate risk PCa 
(PSA≤20; one or two of the risk factors; T3, Gleason ≥7, PSA 
10-20). No hormones were used. Patients were randomized to 
either conventionally fractionated RT (39 fr; 2.0 Gy/fr) over 
7 weeks, or to a schedule with extreme hypofractionation (7 
fr; 6.1 Gy/ fr) in 2.5 weeks (always including two weekends). 
The two treatment arms are designed to be equieffective for 
late normal tissue complications assuming α/β=3 Gy. Primary 
endpoint will be mature within 2 years, and toxicity data will 
be reported by late this year. 
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Brachytherapy has always represented the most focal means 
on delivering radiationh having the advantages of the inverse 
square law around the radiation source which ensures 
delivery of an intense high dose within the implant and a 
rapid fall dose outside. These characteristics mean that 
brachytherapy can deliver very high doses to the prostate 
gland with in the tolerance doses of bladder and rectum and 
that the characteristics of dose distribution with in the 
implant mean that the volume receiving 150% and 200% 
prescribed peripheral dose (the 150 and the 200) are 
considerably greater than can be achieved with any external 
beam technique.  
Brachytherapy as a boost can be used in two distinct ways. 
First is as a boost to the whole gland following external beam 
radiotherapy. There is now grade a level I evidence from 
randomised controlled trials that both low dose rate and high 
dose rate brachytherapy achieve effective dose escalation 
and consequently better biochemical relapse free survival.  
There is also increasing interest in the use of brachytherapy 
to deliver a focal boost to dominant lesions defined on multi-
parametric MR scanning and mapping template biopsies. Thus 
within a whole gland brachytherapy volume sub volumes can 
be defined within which the dose can be further escalated. 
Planning studies have confirmed the feasibility of this 
approach with both low dose rate and high dose rate 
brachytherapy and the requirements for catheter or seed 
placement to achieve these endpoints has been described. 
The clinical application of this approach is still in its infancy 
although early results confirm its feasibility.  
Summary: both low dose rate and high dose rate 
brachytherapy offer optimal means of focal dose delivery 
within the prostate gland. The use of this modality for whole 
gland treatment is now well established sound evidence base. 
Emerging application sub volume posts to dominant tumour 
volumes is under investigation. 
 
 
 
 
 
 
